Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + bevacizumab + GEMOX for advanced biliary tract cancer
ChiCTR2100049830Phase 2Recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Aug 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, bevacizumab, gemcitabine and oxaliplatin in biliary cancer, sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: Objective response rate. Started Aug 2021; status: recruiting.
02
Drugs
atezolizumabbevacizumabgemcitabineoxaliplatin
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2100049830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049830.